Objective: To evaluate the pharmacodynamics and toxicology of
JINPUYILIUPIAN for its clinical application Methods: Vivo
tests were conducted on mouse hepatic cancer H\-\{22\} of solid and ascites types, and on mouse sarcoma S\-\{180\}; tests of the immunity of mouse bearing sarcoma S\-\{180\} including carbon particle clearance method and specific hemolytic reactions were induced by chicken red blood cell in mouse, hot plate method for analgesic test, antidote tests for chemotherapeutic cyclophamide, acute and chronic toxicity tests Results: The tested tablet preparation
JINPUYILIUPIAN significantly inhibited the growth of tumours S\-\{180\} and H\-\{22\} in mice with average inhibiting rates of 43 6% and 26 2% respectively, prolonged the survival time of the tested mice with average prolonging rates of 60 9% and 29 7%, increased the clearance for carbon particles and HC\-\{50\}(index for 50% haemolysis) in mice bearing tumour, increased the leukocytes and counteracted the toxic action of
cyclophophamide on leukocytes, and increased the threshold of hot plate in the tested mice Acute tocicity tests showed that daily intragastric administration of 2 doses(equivalent to 832 times of clinical daily dose) of the preparation did not result in toxic reactions in tested mice, and no adverse reaction was found in the chronic toxicity tests in rats with daily dose equivalent to 107, 64 and 32 times of clinical daily dose for 14 weeks respectively Conclusion: The tested tablet preparation JINPUYILIUPIAN inhibits the growth of tumours S\-\{180\} and H\-\{22\} in mice, prolongs the survival time and enhances the immunity of tumor bearing mice, and counteracts the toxic action of cyclophophamide No adverse reaction foung was in long term administration